We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
and Helsinn Group today announced that (FDA) has approved Truseltiq (infigratinib) under the accelerated approval program for the treatment of patients with previously-treated locally advanced or metastatic CCA harboring an FGFR2 fusion